Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;67(2):256-259.
doi: 10.4103/indianjpsychiatry.indianjpsychiatry_794_24. Epub 2025 Feb 19.

Tapentadol as a drug of abuse - A preliminary report

Prakrithi Shivaprakash  1 , Lekhansh Shukla  1 , Sourabh Joshi  1 , Jayant Mahadevan  1 , Arun Kandasamy  1 , Prabhat K Chand  1 , Vivek Benegal  1 , Pratima Murthy  1
Affiliations

Tapentadol as a drug of abuse - A preliminary report

Prakrithi Shivaprakash et al. Indian J Psychiatry. 2025 Feb.

Abstract

Background: Tapentadol is a dual action opioid analgesic with emerging data on abuse and diversion.

Aim: This study describes tapentadol abuse, clinical presentation, and treatment patterns.

Methods: We reviewed patients seeking help for tapentadol use (2017-2023) at a South Indian tertiary hospital. We collected data on sociodemographics, clinical profiles, and treatment, including buprenorphine dose and dose limiting side effects.

Results: Of 933 opioid use disorder cases, 228 involved tapentadol. Most (89%) initiated opioid use with tapentadol, and 93% injected dissolved tablets. 80% were diagnosed with opioid dependence. Over half required inpatient treatment. 75% received buprenorphine, but tolerability was poor. The median first day dose was 0.8 mg (IQR = 0.4-2), and the maintenance dose was 4 mg (IQR = 2-8), with nausea being the main side effect.

Conclusion: We can conclude that Tapentadol is prone to abuse and dependence. These patients have poor buprenorphine tolerability and receive low maintenance doses. Further research is needed on effective opioid agonist treatment for tapentadol dependence.

Keywords: Buprenorphine; Tapentadol; opiate substitution treatment; opioid-related disorders; people who inject drugs.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain. 2018;22:827–44. - PubMed
    1. World Health Organisation . Geneva: World Health Organisation; 2015. WHO Expert Committee on Drug Dependence - Thirty sixth report. Available from: https://ecddrepository.org/en/tapentadol . [Last accessed on 2024 Sep 12] - PubMed
    1. Rzetelny A, Meske D, Patel P, Passik S. Tapentadol is the least common opioid found in admission urine drug-test results at an intensive outpatient opioid-use disorder treat-ment program in Ohio: A brief report. J Opioid Manag. 2021;17:13–7. - PubMed
    1. Mukherjee D, Shukla L, Saha P, Mahadevan J, Kandasamy A, Chand P, et al. Tapentadol abuse and dependence in India. Asian J Psychiatr. 2020;49:101978. doi: 10.1016/j.ajp.2020.101978. - PubMed
    1. Central Drugs Standard Control Organisation New Drugs Approved by CDSCO: Central Drugs Standard Control Organisation. 2011. Available from: https://cdscoonline.gov.in/CDSCO/Drugs . [Last accessed on 2024 Mar 22]

LinkOut - more resources